Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
about
Genome-wide case-control study of musculoskeletal adverse events and functional genomics in women receiving aromatase inhibitors: going beyond associationsProspective study to assess fluid accumulation and tenosynovial changes in the aromatase inhibitor-induced musculoskeletal syndrome: 2-year follow-up data.In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors.Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole.Joint symptoms, aromatase inhibitor-related adverse reactions, are indirectly associated with decreased serum estradiol.Changes in bone biomarker concentrations and musculoskeletal symptoms among breast cancer patients initiating aromatase inhibitor therapy and women without a history of cancer.Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expressionTSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression.Mammographic breast density response to aromatase inhibition.Novel hormone treatment of benign metastasizing leiomyoma: an analysis of five cases and literature review.Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.The effect of grape seed extract on estrogen levels of postmenopausal women: a pilot study.Pharmacogenomics of endocrine therapy in breast cancer.Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation.Pharmacogenomics of third-generation aromatase inhibitors.Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer.Safety of aromatase inhibitor therapy in breast cancer.Germline genetic predictors of aromatase inhibitor concentrations, estrogen suppression and drug efficacy and toxicity in breast cancer patients.Molecular basis of aromatase inhibitor associated arthralgia: known and potential candidate genes and associated biomarkers.Use of anastrozole in the chemoprevention and treatment of breast cancer: A literature review.Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy.Androgen levels during adjuvant endocrine therapy in postmenopausal breast cancer patients.Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteinsEffects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.Polymorphisms in ABCB1 and CYP19A1 genes affect anastrozole plasma concentrations and clinical outcomes in postmenopausal breast cancer patients.Pharmacokinetics, pharmacodynamics, safety and tolerability of an intravaginal ring releasing anastrozole and levonorgestrel in healthy premenopausal women: a Phase 1 randomized controlled trial.SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway.
P2860
Q34423538-850850E7-C3CA-478F-8EC7-5DABACFC52DFQ34434858-DA70333A-73A2-47B5-9743-A553D4321836Q34457429-FE08D6C7-7078-4B8B-83FA-9E49FC959AB6Q35029533-72B296C9-4AD2-48BD-9935-68C2EC69EB82Q35118969-78E0B6CC-FB95-4541-8CC7-B645284F9296Q35687686-997EB4B3-DDEA-4F7E-A2B3-781E641ADEE3Q36157257-590D69B5-1D00-4D56-A944-3636C9124834Q36245513-80372812-1635-498B-9CB5-660DBD2548FBQ36714877-0E272E43-83CB-409F-A49B-C1695B187B7CQ36778183-2D62482C-B3B3-491C-8380-E7CA0715D100Q36901710-FFDE0FB7-6F0B-4C73-BB2F-9EF6BA77ECB7Q36927755-34C19768-0A98-4058-B4FD-AFD268DE9F19Q37064849-11F29398-E90F-4299-97F9-2E8F9C4B5B4FQ37588045-46E73019-650C-4B52-84B7-56A37865486AQ37633691-A69BDDF5-EFD4-4871-8750-0C09DB0A0A28Q38010777-54DC9FB3-8FCA-470B-AAAA-C1D9119B0E5CQ38103593-53F3CECD-A4A0-4D27-898E-04CBD97FEB0AQ38522924-A6343E97-91B9-448D-BA96-01808CA7DB02Q38739248-62490D6F-05B1-4AF9-8C72-3810769FA97FQ38956073-F9FB0C4B-7590-4CEB-AFE4-7A7E155C71DCQ39373643-2196ABFE-90A8-46A9-A854-88511B423D5AQ45846594-0206B0E9-316D-4464-8ADC-BD08EF6816E3Q46192322-9D40C233-C181-4E0A-8125-7C1A0A37A0CEQ47215160-EE18A36F-7374-4C4A-BDB7-DFC99A89E8ABQ47594270-FEFDBCBC-20AE-4CBB-B67A-9F5B03F204A0Q51387487-13425091-C970-4112-ABE9-105486FD5084Q52850128-4FA70F64-A432-4516-AFAB-E58FE564D885Q55017654-1F03EC98-44FC-4F8D-A2E4-7949DCC7F569
P2860
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Variation in anastrozole metab ...... omen with early breast cancer.
@ast
Variation in anastrozole metab ...... omen with early breast cancer.
@en
type
label
Variation in anastrozole metab ...... omen with early breast cancer.
@ast
Variation in anastrozole metab ...... omen with early breast cancer.
@en
prefLabel
Variation in anastrozole metab ...... omen with early breast cancer.
@ast
Variation in anastrozole metab ...... omen with early breast cancer.
@en
P2093
P2860
P50
P1433
P1476
Variation in anastrozole metab ...... omen with early breast cancer.
@en
P2093
Aman U Buzdar
Clark V Williard
Daniel J Schaid
Donald W Northfelt
Edith A Perez
James N Ingle
Matthew P Goetz
Randy A Weintraub
P2860
P304
P356
10.1158/0008-5472.CAN-09-3024
P407
P577
2010-03-30T00:00:00Z